Unique Ingredient Identifier RS7A450LGA is listed as a ingredient substance
| RN | 68-04-2 |
| EC | 200-675-3 |
| NCIT | C66542 |
| RXCUI | 1310549 |
| PUBCHEM | 6224 |
| MF | C6H5O7.3Na |
| INCHI KEY | HRXKRNGNAMMEHJ-UHFFFAOYSA-K |
| SMILES | [Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O |
UNII RS7A450LGA ANHYDROUS TRISODIUM CITRATE is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| IM - IV | INJECTION | 16 % |
| INHALATION | SUSPENSION | 0.9 mg/2mL |
| INTRA-ARTERIAL | INJECTION | NA |
| INTRA-ARTICULAR | INJECTION | 1 % |
| INTRABURSAL | INJECTION | 1 % |
| INTRALESIONAL | INJECTION | 0.96 %W/V |
| INTRAMUSCULAR | INJECTION | 0.96 %W/V |
| INTRAVENOUS | INJECTION | 0.96 %W/V |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 6.99 % |
| IV(INFUSION) | CONCENTRATE | 2.4 % |
| IV(INFUSION) | INJECTION | 16 % |
| NASAL | SPRAY | 1.27 % |
| NASAL | SPRAY, METERED | 0.001 % |
| OPHTHALMIC | SOLUTION | NA |
| ORAL | FOR SUSPENSION | 9 MG/5ML |
| ORAL | GRANULE | NA |
| ORAL | GRANULE, EFFERVESCENT | NA |
| ORAL | LIQUID,EXTENDED RELEASE | 3.9 MG/ML |
| ORAL | POWDER, FOR ORAL SUSPENSION | 19.31 MG/5ML |
| ORAL | POWDER, FOR RECONSTITUTION | 7.5 MG/5ML |
| ORAL | POWDER, FOR SOLUTION | 48 MG/5ML |
| ORAL | POWDER, FOR SUSPENSION | 66.7 MG/5ML |
| ORAL | SOLUTION | 30 MG/5ML |
| ORAL | SUSPENSION | 7.5 MG/5ML |
| ORAL | SYRUP | 7.95 MG/5ML |
| ORAL | TABLET | 28 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, EFFERVESC | 935 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 15 MG |
| SOFT TISSUE | INJECTION | 0.96 %W/V |
| SUBLINGUAL | FILM | 1.34 MG |
| SUBLINGUAL | TABLET | 2.68 MG |
| TOPICAL | CREAM | 0.05 %W/W |
| TOPICAL | CREAM, EMULSION, SUSTAINED RELEASE | 0.12 %W/W |
| TOPICAL | EMULSION, CREAM | 0.28 %W/W |
| TOPICAL | LOTION | 0.075 %W/W |